KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Cost of Revenue (2017 - 2025)

Cardlytics (CDLX) has disclosed Cost of Revenue for 9 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 33.67% year-over-year to $7.5 million, compared with a TTM value of $39.5 million through Dec 2025, down 25.02%, and an annual FY2025 reading of $39.5 million, down 25.02% over the prior year.
  • Cost of Revenue was $7.5 million for Q4 2025 at Cardlytics, down from $7.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $22.0 million in Q2 2022 and bottomed at $7.5 million in Q4 2025.
  • Average Cost of Revenue over 5 years is $14.5 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 63.99% in 2021, then tumbled 40.25% in 2025.
  • Year by year, Cost of Revenue stood at $19.0 million in 2021, then decreased by 11.44% to $16.8 million in 2022, then decreased by 16.13% to $14.1 million in 2023, then dropped by 19.62% to $11.3 million in 2024, then crashed by 33.67% to $7.5 million in 2025.
  • Business Quant data shows Cost of Revenue for CDLX at $7.5 million in Q4 2025, $7.9 million in Q3 2025, and $11.3 million in Q2 2025.